Product nameAnti-CARD15 antibody
See all CARD15 primary antibodies
DescriptionGoat polyclonal to CARD15
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Chimpanzee
- Human peripheral blood mononucleocytes.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 0.5% BSA, 0.5% Tris buffered saline
Concentration information loading...
PurityImmunogen affinity purified
Purification notesPurified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Our Abpromise guarantee covers the use of ab53518 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Peptide ELISA: antibody detection limit dilution 1:64,000.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionInduces NF-kappa-B via RICK (CARDIAK, RIP2) and IKK-gamma. Confers responsiveness to intracellular bacterial lipopolysaccharides (LPS).
Involvement in diseaseDefects in NOD2 are the cause of Blau syndrome (BS) [MIM:186580]. BS is a rare autosomal dominant disorder characterized by early-onset granulomatous arthritis, uveitis and skin rash.
Defects in NOD2 are a cause of susceptibility to inflammatory bowel disease type 1 (IBD1) [MIM:266600]. IBD1 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.
Defects in NOD2 are the cause of sarcoidosis early-onset (EOS) [MIM:609464]. EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Early-onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement.
Sequence similaritiesContains 2 CARD domains.
Contains 9 LRR (leucine-rich) repeats.
Contains 1 NACHT domain.
- Information by UniProt
- ACUG antibody
- Arthrocutaneouveal granulomatosis antibody
- BLAU antibody
Anti-CARD15 antibody (ab53518) at 0.1 µg/ml + Human Peripheral Blood Mononucleocyte lysate (35µg protein in RIPA buffer).
Predicted band size: 115 kDa
Observed band size: 100 kDa why is the actual band size different from the predicted?
Additional bands at: 60 kDa. We are unsure as to the identity of these extra bands.
Primary incubation was 1 hour. Detected by chemiluminescence.
ab53518 has not yet been referenced specifically in any publications.